SG10201803996WA - Anti-tuberculosis stable pharmaceutical composition in a form of a dispersible tablet comprising granules of isoniazid and granules of rifapentine and its process of preparation - Google Patents

Anti-tuberculosis stable pharmaceutical composition in a form of a dispersible tablet comprising granules of isoniazid and granules of rifapentine and its process of preparation

Info

Publication number
SG10201803996WA
SG10201803996WA SG10201803996WA SG10201803996WA SG10201803996WA SG 10201803996W A SG10201803996W A SG 10201803996WA SG 10201803996W A SG10201803996W A SG 10201803996WA SG 10201803996W A SG10201803996W A SG 10201803996WA SG 10201803996W A SG10201803996W A SG 10201803996WA
Authority
SG
Singapore
Prior art keywords
granules
rifapentine
isoniazid
preparation
pharmaceutical composition
Prior art date
Application number
SG10201803996WA
Inventor
Prajapati Dilip
Prasad Kum
Khullar Praveen
Kumar Ramesh
Kumar Shakti
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51211798&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG10201803996W(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of SG10201803996WA publication Critical patent/SG10201803996WA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A61K31/06—Phenols the aromatic ring being substituted by nitro groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

ANTI-TUBERCULOSIS STABLE PHARMACEUTICAL COMPOSITION IN A FORM OF A DISPERSIBLE TABLET COMPRISING GRANULES OF ISONIAZID AND GRANULES OF RIFAPENTINE AND ITS PROCESS OF PREPARATION 5 The present invention relates to an oral pharmaceutical fixed dose composition in a form of a dispersible tablet for use in the treatment of tuberculosis, said oral pharmaceutical composition comprising: 10 a) granules comprising isoniazid and at least one intragranular excipient, b) granules comprising rifapentine and at least one intragranular excipient, and c) at least one extragranular excipient, and 15 to its process of preparation. [No Figure] 20
SG10201803996WA 2013-07-26 2014-07-22 Anti-tuberculosis stable pharmaceutical composition in a form of a dispersible tablet comprising granules of isoniazid and granules of rifapentine and its process of preparation SG10201803996WA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN3342CH2013 2013-07-26

Publications (1)

Publication Number Publication Date
SG10201803996WA true SG10201803996WA (en) 2018-06-28

Family

ID=51211798

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201510732VA SG11201510732VA (en) 2013-07-26 2014-07-22 Anti-tuberculosis stable pharmaceutical composition in a form of a dispersible tablet comprising granules of isoniazid and granules of rifapentine and its process of preparation
SG10201803996WA SG10201803996WA (en) 2013-07-26 2014-07-22 Anti-tuberculosis stable pharmaceutical composition in a form of a dispersible tablet comprising granules of isoniazid and granules of rifapentine and its process of preparation

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG11201510732VA SG11201510732VA (en) 2013-07-26 2014-07-22 Anti-tuberculosis stable pharmaceutical composition in a form of a dispersible tablet comprising granules of isoniazid and granules of rifapentine and its process of preparation

Country Status (18)

Country Link
US (1) US9814680B2 (en)
EP (1) EP3024444A1 (en)
JP (2) JP2016539110A (en)
CN (1) CN105407876B (en)
AU (1) AU2014295099B2 (en)
CA (1) CA2918528A1 (en)
CL (1) CL2016000183A1 (en)
HK (1) HK1218861A1 (en)
IL (1) IL243369A0 (en)
MX (1) MX2016001155A (en)
PE (1) PE20160245A1 (en)
PH (1) PH12016500119A1 (en)
RU (1) RU2694056C2 (en)
SA (1) SA516370446B1 (en)
SG (2) SG11201510732VA (en)
TW (1) TWI630911B (en)
WO (1) WO2015011162A1 (en)
ZA (1) ZA201600110B (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2918828A1 (en) 2013-07-26 2015-01-29 Sanofi Antitubercular composition comprising rifampicin, isoniazid, ethambutol and pyrazinamide and its process of preparation
KR20230106643A (en) * 2020-11-09 2023-07-13 리얼타 라이프 사이언시즈, 인크. Peptide preparations and methods of use
CN112730657A (en) * 2020-12-18 2021-04-30 卓和药业集团有限公司 Analysis and detection method for rifapentine content

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1217912A (en) * 1997-11-26 1999-06-02 岑冠新 Compound rifapentine preparation and preparation method thereof
TR200200966T1 (en) * 2000-08-09 2002-09-23 Panacea Biotec Limited New pharmaceutical compositions and preparation processes of tubercular drugs
EP1334716A4 (en) * 2000-10-16 2009-04-29 Daiichi Seiyaku Co Medicinal compositions quickly disintegrating in the oral cavity and process for producing the same
BR0116994A (en) 2001-04-27 2004-03-02 Lupin Ltd An improved process for preparing a composition comprising a fixed dose combination (fdc) of four antituberculosis drugs
US20050059719A1 (en) 2003-09-16 2005-03-17 Badawy Sherif Ibrahim Farag Solid dosage formulation containing a Factor Xa inhibitor and method
JP5105818B2 (en) * 2005-10-05 2012-12-26 大塚製薬株式会社 Pharmaceutical composition
TW201233389A (en) 2005-10-05 2012-08-16 Otsuka Pharma Co Ltd Antituberculous therapeutic drugs and kit containing the same
US20090295921A1 (en) * 2005-10-12 2009-12-03 Pioneer Corporation Vehicle-mounted photographing device and method of measuring photographable range of vehicle-mounted camera
CN1989966B (en) 2005-12-30 2011-06-08 重庆华邦制药股份有限公司 Pharmaceutical composition comprising rifamoin and isoniazid
CN1857280A (en) * 2006-04-11 2006-11-08 济南帅华医药科技有限公司 Slow released compound antituberculotic preparation
WO2009020666A1 (en) * 2007-08-06 2009-02-12 Insys Therapeutics Inc. Oral cannabinoid liquid formulations and methods of treatment
KR101197277B1 (en) * 2009-02-05 2012-11-05 (주) 벡스코아 Oral Solid Preparation For Treatment And Prevention Of Tuberculosis
WO2011012987A1 (en) 2009-07-31 2011-02-03 Cadila Pharmaceuticals Ltd. Pharmaceutical composition of isoniazid
US20130129791A1 (en) * 2010-05-04 2013-05-23 Mahmut Bilgic Preparations of effervescent formulations comprising second and third generation cephalosporin and uses thereof
WO2012013756A2 (en) 2010-07-28 2012-02-02 Laboratoires Pharma 5 Method for preparing tablets combining rifampicin, isoniazid, pyrazinamide and, optionally, ethambutol
US8470365B2 (en) * 2010-07-29 2013-06-25 Taiwan Biotech Co., Ltd. Process for preparation of anti-tubercular combination and pharmaceutical composition prepared therefrom
CA2918828A1 (en) 2013-07-26 2015-01-29 Sanofi Antitubercular composition comprising rifampicin, isoniazid, ethambutol and pyrazinamide and its process of preparation
CA2918827A1 (en) 2013-07-26 2015-01-29 Sanofi Anti-tuberculosis stable pharmaceutical composition in a form of a coated tablet comprising granules of isoniazid and granules of rifapentine and its process of preparation

Also Published As

Publication number Publication date
EP3024444A1 (en) 2016-06-01
AU2014295099A1 (en) 2016-02-11
TW201601723A (en) 2016-01-16
JP6476331B2 (en) 2019-02-27
TWI630911B (en) 2018-08-01
CN105407876B (en) 2019-08-30
RU2016106328A (en) 2017-08-31
HK1218861A1 (en) 2017-03-17
MX2016001155A (en) 2016-04-29
PE20160245A1 (en) 2016-05-10
RU2694056C2 (en) 2019-07-09
ZA201600110B (en) 2017-04-26
SG11201510732VA (en) 2016-01-28
CL2016000183A1 (en) 2016-07-01
JP2016539110A (en) 2016-12-15
US9814680B2 (en) 2017-11-14
AU2014295099B2 (en) 2019-07-11
CA2918528A1 (en) 2015-01-29
JP2018123147A (en) 2018-08-09
CN105407876A (en) 2016-03-16
PH12016500119A1 (en) 2016-04-25
IL243369A0 (en) 2016-02-29
SA516370446B1 (en) 2018-09-13
WO2015011162A1 (en) 2015-01-29
US20160184231A1 (en) 2016-06-30

Similar Documents

Publication Publication Date Title
JP2015057451A5 (en)
MX2016009427A (en) Modified release formulations of pridopidine.
NZ593045A (en) Pharmaceutical dosage form comprising nifedipine or nisoldipine and an angiotensin-ii antagonist and/or a diuretic
MA39765A (en) Pharmaceutical formulations of a pan-raf kinase inhibitor, processes for their preparation, and methods of use
SG10201805267UA (en) Piperazine derivatives having multimodal activity against pain
PH12015500823A1 (en) Modified release formulations for oprozomib
MX2018000546A (en) Pharmaceutical composition containing celecoxib and tramadol.
PH12016502233A1 (en) (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine
MX2017013636A (en) Tamper-resistant fixed dose combination providing fast release of two drugs from different particles.
SA516370446B1 (en) Anti-tuberculosis stable pharmaceutical composition in a form of a dispersible tablet comprising granules of isoniazid and granules of rifapentine and its process of preparation
PH12016500120A1 (en) Anti-tuberculosis stable pharmaceutical composition in a form of a coated tablet comprising granules of isoniazid and granules of rifapentine and its process of preparation
MX2016008027A (en) Use of laquinimod to delay huntington's disease progression.
MX2017005163A (en) Onapristone extended-release compositions and methods.
MX2017013633A (en) Tamper-resistant fixed dose combination providing fast release of two drugs from particles.
MX2018010065A (en) Oral dosage form comprising rifaximin in form beta.
MX2018011293A (en) Prolonged release pharmaceutical composition comprising cysteamine or salt thereof.
MX2017013643A (en) Tamper-resistant fixed dose combination providing fast release of two drugs from particles and a matrix.
AU2017260751A1 (en) Tablet-in-tablet pharmaceutical composition comprising cyclophosphamide and capecitabine
MX2017013634A (en) Tamper-resistant fixed dose combination providing fast release of two drugs from particles and a powder.
MX2015011099A (en) Pharmaceutical compositions of donepezil having specific in vitro dissolution profile or pharmacokinetics parameters.
IN2013MU02110A (en)
IN2013MU02111A (en)
UA97982U (en) DRESSING MEDICINE FOR TABLETS
IN2013MU02286A (en)
IN2013MU01154A (en)